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Abstract: Rearranged during transfection (RET) is the tyrosine kinase receptor that under normal
circumstances interacts with ligand at the cell surface and mediates various essential roles in a
variety of cellular processes such as proliferation, differentiation, survival, migration, and metabolism.
RET plays a pivotal role in the development of both peripheral and central nervous systems. RET is
expressed from early stages of embryogenesis and remains expressed throughout all life stages.
Mutations either activating or inhibiting RET result in several aggressive diseases, namely cancer and
Hirschsprung disease. However, the physiological ligand-dependent activation of RET receptor is
important for the survival and maintenance of several neuronal populations, appetite, and weight
gain control, thus providing an opportunity for the development of disease-modifying therapeutics
against neurodegeneration and obesity. In this review, we describe the structure of RET, its signaling,
and its role in both normal conditions as well as in several disorders. We highlight the differences in
the signaling and outcomes of constitutive and ligand-induced RET activation. Finally, we review the
data on recently developed small molecular weight RET agonists and their potential for the treatment
of various diseases.
Keywords: rearranged in transfection (RET); neurodegeneration; obesity; cancer; RET agonist;
neurorestoration; retinitis pigmentosa; hirschsprung disease; glial cell line-derived neurotrophic
factor (GDNF) family ligands (GFLs); growth differentiation factor 15 (GDF15)
1. Introduction
Receptor tyrosine kinases (RTKs) are transmembrane proteins conveying extracellular stimulus
inside the cell. The members of RTKs are expressed in almost every if not all cells in the organism
and play pivotal roles in different cellular functions such as proliferation, cellular differentiation,
cell survival, cell migration, and metabolism. There are 58 different RTKs in humans with similar
molecular structure, which are activated by ligands binding to their extracellular domain [1].
All RTKs have an extracellular domain that interacts with a ligand (directly or indirectly) and an
intracellular kinase domain that is activated upon ligand binding and catalyzes autophosphorylation.
These two domains are connected by a transmembrane domain. Apart from these three structural
domains, there is a juxtamembrane domain that was initially thought to be just a mechanical linker
between two parts of the protein. However, recent studies show that it may also regulate the function
of at least some RTKs [2].
Ligand interaction with extracellular domains of RTKs promotes their dimerization or
oligomerization and triggers the phosphorylation of tyrosine residues in their kinase domains.
Phosphorylated tyrosine residues recruit adapter proteins and trigger the activation of intracellular
signaling cascades [1].
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The main objective of this review is to highlight the importance of rearranged in transfection (RET)
in health and disease conditions. The present review is focused on the structure, function, and role
of RET in neurodegeneration, obesity, and cancer. Furthermore, this review updates recent findings
on how RET can be targeted with small molecules for the treatment of various disease conditions.
RET is unique as unlike other RTKs, it does not bind to the ligand directly. Instead, it forms a tripartite
complex consisting of a dimeric ligand, two molecules of ligand-binding co-receptors (either glial
cell line-derived neurotrophic factor (GDNF) family receptor alpha (GFRα) or GDNF family receptor
alpha-like (GFRAL) and two molecules of RET. This, on one hand, provides an opportunity to target
it selectively in diseases via co-receptors or the interaction surface between a co-receptor and RET.
This is important because the kinase domain of RET is structurally similar to the kinase domains of
other RTKs; therefore, it is difficult to find selective molecules acting via the kinase domain. On the
other hand, GFRα1 can regulate RET signaling in a way that for a particular stimulus, signaling bias
may exist [3], and this may allow RET to orchestrate cellular processes more precisely. However,
disturbances in cellular levels of RET and GFRα co-receptors can lead to undesirable consequences,
such as RET activation in the absence of a ligand, which can potentially result in the formation of
malignant tumors [4,5].
2. RET Receptor Tyrosine Kinase
RET was identified as an oncogene activated by the recombination of DNA [6,7]. Unlike other RTKs,
RET contains cadherin-like repeats in the extracellular domain (Figure 1). The N-terminal region of RET
consists of four cadherin-like domains (CLDs 1-4) each of 110 amino acid residues and a cysteine-rich
region. The calcium-binding site is present between CLD2 and CLD3. The N-terminal region of
RET encodes a signal sequence (1–28 residues) that directs RET to the endoplasmic reticulum (ER).
The extracellular domain of RET possesses 12 glycosylation sites that undergo extensive glycosylation
in ER to form 150 KDa RET. The further modification of RET occurs in Golgi to form 170 KDa mature
RET. Glycosylation increases the stability of the mature RET [8,9]. Inactivation mutations in the
intracellular and extracellular domains are associated with Hirschsprung’s disease (HSCR disease),
which is explained later in the text (see Section 3.3). The binding of ligand is calcium dependent,
and calcium ions are required for the RET–ligand complex formation, which further induces RET
autophosphorylation [10,11]. Furthermore, calcium is necessary for the proper folding of RET in the
ER [12].
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Figure 1. Rearranged in transfection (RET) receptor structure and its intracellular signaling pathway. 
The extracellular domain of RET contains four cadherin-like repeats and a cysteine-rich domain. Ca2+ 
ions bind to the extracellular cadherin-like domains of RET, which is required for its activation. The 
intracellular domain of RET contains a typical kinase domain. RET has three isoforms (RET9, RET43, 
and RET51), which differ in their carboxy-terminal amino acids. RET9 and RET51 are evolutionarily 
highly conserved. RET is phosphorylated at multiple tyrosine residues when activated by different 
ligands. Phosphorylated tyrosine residues serve as docking sites for various adaptor proteins that 
induce the activation of downstream signaling pathways essential for cell growth, proliferation, 
survival, differentiation, or appetite control. The black line indicates the binding of adapter protein 
and the activation of downstream signaling pathways. The red line indicates mutations in the RET 
region that are responsible for diseases such as multiple endocrine neoplasia (MEN) syndromes 2A 
and 2B and Hirschsprung disease (HSCR). 
The extracellular region also includes 120 residues of the cysteine-rich region, which is adjacent 
to the transmembrane domain. The intracellular domain of RET contains a typical kinase domain. 
The alternative splicing of RET results in three different protein isoforms, i.e., RET9 (1072 amino 
acids), RET43 (1106 amino acids), and RET51 (1114 amino acids) [13,14]. In most tissues, all these 
isoforms are co-expressed. However, the expression of the RET9 isoform is much higher than that of 
the RET51 isoform, while the expression of RET43 is much lower compared to the RET51 isoform 
[14]. The targeted mutagenesis of the mouse genome, which either expresses RET9 or RET51, revealed 
that mice lacking RET51 are viable and appear normal, whereas mice lacking RET9 have defects in 
the innervation of the gut and renal development [14,15]. The ligand-induced dimerization of RET 
leads to the autophosphorylation of various tyrosine residues and further activates intracellular 
signaling cascades, which affects a number of cellular processes [3]. 
In normal conditions, RET is activated by glial cell line-derived neurotrophic factor (GDNF) 
family ligands (GFLs). GFLs belong to the transforming growth factor beta (TGFb) superfamily. 
Figure 1. Rearranged in transfection (RET) receptor structure and its intracellular signaling pathway.
The extracellular domain of RET contains four cadherin-like repeats and a cysteine-rich domain.
Ca2+ ions bind to the extracellular cadherin-like domains of RET, which is required for its activation.
The intracellular domain of RET contains a typical kinase domain. RET has three isoforms (RET9, RET43,
and RET51), which differ in their carboxy-terminal amino acids. RET9 and RET51 are evolutionarily
highly conserved. RET is phosphorylated at multiple tyrosine residues when activated by different
ligands. Phosphorylated tyrosine residues serve as docking sites for various adaptor proteins that
induce the activation of downstream signaling pathways essential for cell growth, proliferation, survival,
differentiation, or appetite control. The black line indicates the binding of adapter protein and the
activation of downstream signaling pathways. The red line indicates mutations in the RET region that
are responsible for diseases such as multiple endocrine neoplasia (MEN) syndromes 2A and 2B and
Hirschsprung disease (HSCR).
The extracellular region also includes 120 residues of the cysteine-rich region, which is adjacent
to the transmembrane domain. The intracellular domain of RET contains a typical kinase domain.
The alternative splicing of RET results in three different protein isoforms, i.e., RET9 (1072 amino
acids), RET43 (1106 amino acids), and RET51 (1114 amino acids) [13,14]. In most tissues, all these
isoforms are co-expressed. However, the expression of the RET9 isoform is much higher than that of
the RET51 isoform, while the expression of RET43 is much lower compared to the RET51 isoform [14].
The targeted mutagenesis of the mouse genome, which either expresses RET9 or RET51, revealed that
mice lacking RET51 are viable and appear normal, whereas mice lacking RET9 have defects in the
innervation of the gut and renal development [14,15]. The ligand-induced dimerization of RET leads
to the autophosphorylation of various tyrosine residues and further activates intracellular signaling
cascades, which affects a number of cellular processes [3].
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In normal conditions, RET is activated by glial cell line-derived neurotrophic factor (GDNF) family
ligands (GFLs). GFLs belong to the transforming growth factor beta (TGFb) superfamily. Traditionally,
four proteins—GDNF, neurturin (NRTN), artemin (ARTN), and persephin (PSPN)—were referred to as
GFLs. Recently, another protein, GDF15, was shown to signal via RET. GDF15 is a distant member of
the TGFb superfamily with a close relationship with GFLs. Similar to other TGFb members, GDF15 also
includes a highly conserved pattern of seven cysteine residues in its mature domain. Of the seven
cysteine residues, six form highly stable intra-chain disulfide bonds, and the remaining one forms an
inter-chain disulfide bond. Similar to other members, GDF15 is secreted as a dimeric protein. Therefore,
it can be considered as a 5th GFL [16,17].
GDNF at first binds glial cell line-derived neurotrophic factor family receptor alpha 1 (GFRα1)
and consequently forms a tripartite complex with RET. Other members of GFLs such as NRTN binds to
GFRα2, ARTN binds to GFRα3, and PSPN binds to GFRα4 in order to form a complex with RET and
induce signaling [18,19]. However, preferences of the ligand and co-receptor might change, making the
co-receptor unselective. For example, GDNF can also bind to GFRα2 and NRTN, ARTN, and PSPN
can also bind to GFRα1 [20–22]. GDF15 binds to a distant orphan member of the GFRα family called
GFRAL and further forms a complex with RET. Interactions between GDF15 and GFRα co-receptor are
not reported [23–26].
The binding of GFLs to GFRα co-receptors recruits two molecules of RET receptor into
lipid rafts [27,28]. As a result, the formation of a signaling complex is completed and the trans
autophosphorylation of tyrosine residues on the intracellular domain of RET occurs. The intracellular
domain of RET contains 12 autophosphorylation sites: Y687, Y752, Y806, Y809, Y826, Y900, Y905, Y928,
Y981, Y1015, and Y1062 (Figure 1). The phosphorylated tyrosine residues serve as a docking site for
several adapter proteins, which in turn activate internal signaling. Y905 is the docking site for Grb7/10.
Y1096, which is unique and present only in RET51 long isoform, is the docking site for Grb2, Y1015 is the
docking site for phospholipase C, and Y981 is the docking site for c-Src. Y1062, which is present at the
carboxy terminal of RET, serves as a docking site for several adapter proteins such as Shc, insulin receptor
substrate 1/2 (IRS1/2), fibroblast growth factor receptor substrate 2 (FRS2), downstream of tyrosine kinase
4/5 (DOK1/4/5), and Enigma [18,29]. The phosphorylation of Y1062 activates multiple downstream
signaling pathways such as mitogen-activated protein kinase (MAPK) pathways RAS/extracellular
signal-regulated kinase (ERK), p38MAPK, phosphatidylinositol-3-kinase (PI-3K)/AKT, and Rac/c-Jun
N-terminal kinase (JNK) pathways. The activation of these downstream signaling pathways is necessary
for cell survival, differentiation, proliferation, motility, and functioning [16,18,30].
3. Role of RET in Various Disease States
RET has an important role for the normal development of both peripheral and central nervous
systems and also has functions outside the nervous system. In the central nervous system, RET is
expressed in the ventral midbrain, ganglia layer of retina and olfactory epithelium, undifferentiated
neuroepithelial cells of the ventral neural tube, spinal cord, and the hindbrain [31–33]. In the adult brain,
the expression of RET is restricted to the midbrain, cerebellum, pons, and thalamus [34]. The expression
of RET is also observed in the kidney, thyroid, and lungs [35]. Mutations in RET change the activity of the
receptor and result in various diseases. Mutations that lead to the constitutive activation of RET result
in human multiple endocrine neoplasia (MEN) syndromes 2A and 2B, while mutation that inhibits RET
activation can cause Hirschsprung disease (HSCR) [5,36]. In addition, the ligand-dependent activation
of RET can be important for treating various disease conditions caused by neuronal degeneration or
the disturbances of functional activity of neurons, e.g., Parkinson’s disease (PD), neuropathic pain,
retinitis pigmentosa (RP), and obesity (Figure 2). Here, we present a detailed review on the role of RET
in various disease states.
Int. J. Mol. Sci. 2020, 21, 7108 5 of 21
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 5 of 22 
 
 
Figure 2. Schematic representation of multiple facets of RET protein. RET has a role in both disease 
and normal state. Constitutive activation of RET by mutations leads to human multiple endocrine 
neoplasia (MEN) syndromes 2A and 2B, while mutations that inhibit RET activation can cause 
Hirschsprung disease (HSCR). Ligand-based activation of RET is essential for the development of 
both peripheral and central nervous systems and also outside the nervous system. Therefore, 
targeting RET with agonists can be a useful approach in the treatment of neurodegenerative diseases 
and obesity, and RET antagonists may have a role in the therapy of RET-dependent cancers. 
3.1. Normal Function of RET in DA Neurons and Its Implication in Parkinson’s Disease 
The physiological role of RET has been extensively studied in dopamine neurons because GDNF 
was discovered as a survival factor for these cells [37]. Later, RET was identified as the receptor of 
GDNF through which it triggers the neurite outgrowth and the survival of the central nervous system 
neurons [38]. In mice, RET is expressed in ventral midbrain dopamine neurons from 12.5 days 
postcoitum (dpc) until birth and it remains expressed throughout the lifespan [31]. 
Constitutive Ret knockout mice die shortly after birth due to the absence of kidney. However, 
these mice have normal midbrain dopamine neurons [39,40], suggesting RET as a dispensable 
receptor for the embryonic development of dopamine system. Since RET is the major receptor for 
GDNF signaling, the function of RET was studied in adult midbrain dopamine neurons by the 
selective ablation of RET genes. Among two different studies conducted, both groups reported no 
change in the survival of dopamine neurons during the first 9 months of mouse life [41,42]. However, 
Kramer et al. reported the progressive and late degeneration of dopamine neurons in RET conditional 
knockout mice compared to the age-matched controls when experimental animals were monitored 
for a period of two years. Further, they reported that a loss of neurons was accompanied by 
inflammation and gliosis. These data delineate RET as an important regulator for long-term 
maintenance of the nigrostriatal adult dopamine system [42]. 
MEN2B, an inherited cancer syndrome that is described in more detail in Section 3.6, is often 
caused by the presence of constitutively active RET as a result of point mutation in the gene encoding 
this RTK. In mice overexpressing a variant of the RET gene with a mutation causing MEN2B, the 
levels of dopamine and dopamine metabolites were found to be increased in different brain regions, 
including the striatum. In addition, the level of tyrosine hydroxylase (TH, a key enzyme of dopamine 
synthesis) protein, and TH mRNA levels were also increased along with the number of TH-positive 
cells in the substantia nigra pars compacta (SNpc), suggesting the importance of RET activity in 
maintenance of the dopamine system [35,43]. 
We have also shown that RET is required for the survival of naive cultured dopamine neurons 
as well as for neuroprotection when challenged with neurotoxin. Both RET agonist BT13 and GDNF 
do not promote the survival of cultured embryonic dopamine neurons lacking RET. Furthermore, 
both BT13 and GDNF protect dopamine neurons from 6-OHDA and MPP+ neurotoxin-induced cell 
death only when they express RET [44,45]. Recently, RET signaling activated by its ligand GDNF has 
been shown to prevent Lewy pathology in midbrain dopamine neurons, which further highlights the 
importance of RET for the maintenance of dopamine systems [46]. 
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3.1. Normal Function of RET in DA Neurons and Its Implication in Parkinson’s Disease
The physiological role of RET has been extensively studied in dopamine neurons because GDNF
was discovered as a survival factor for these cells [37]. Later, RET was identified as the receptor
of GDNF through which it triggers the neurite outgrowth and the survival of the central nervous
system neurons [38]. In mice, RET is expressed in ventral midbrain dopamine neurons from 12.5 days
postcoitum (dpc) until birth and it remains expressed throughout the lifespan [31].
Constitutive Ret knockout mice die shortly after birth due to the absence of kidney. However,
these mice have normal midbrain dopamine neurons [39,40], suggesting RET as a dispensable receptor
for the embryonic development of dopamine system. Since RET is the major receptor for GDNF
signaling, the function of RET was studied in adult midbrain dopamine neurons by the selective
ablation of RET genes. Among two different studies conducted, both groups reported no change in the
survival of dopamine neurons during the first 9 months of mouse life [41,42]. However, Kramer et al.
reported the progressive and late degeneration of dopamine neurons in RET conditional knockout
mice compared to the age-matched controls when experimental animals were monitored for a period of
two years. Further, they reported that a loss of neurons was accompanied by inflammation and gliosis.
These data delineate RET as an important regulator for long-term maintenance of the nigrostriatal
adult dopamine system [42].
EN2B, an inherited cancer syndro e that is described in ore detail in Section 3.6, is often
caused by the presence of constitutively active RET as a result of point mutation in the gene encoding
this RTK. In mice overexpressing a variant of the RET gene with a mutation causing MEN2B, the levels
of dopamine and dopamine metabolites were found to be increased in different brain regions, including
the striatum. In addition, the level of tyrosine hydroxylase (TH, a key enzyme of dopamine synthesis)
protein, and TH mRNA levels were also increased along with the number of TH-positive cells in the
substantia nigra pars compacta (SNpc), suggesting the importance of RET activity in maintenance of
the dopamine system [35,43].
e have also shown that RET is required for the survival of naive cultured dopa ine neurons
as well as for neuroprotection when challenged with neurotoxin. Both RET agonist BT13 and GDNF
do not pro ote the survival of cultured e bryonic dopa ine neurons lacking RET. Further ore,
both BT13 and GD F protect dopa ine neurons fro 6-O DA and PP+ neurotoxin-induced cell
death only hen they express RET [44,45]. Recently, RET signaling activated by its ligand GD F has
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been shown to prevent Lewy pathology in midbrain dopamine neurons, which further highlights the
importance of RET for the maintenance of dopamine systems [46].
PD is a progressive neurodegenerative disease that affects most profoundly the dopamine neurons
in the substantia nigra pars compacta (SNpc) [47]. The loss of dopamine neurons results in a deficiency
of dopamine, which then induces motor impairment. Motor disturbances serve as diagnostic symptoms
of PD. Other neuronal populations all over the body are also affected, and their loss or dysfunction
cause non-motor symptoms that can precede motor symptoms by several years and even decades.
There are no drugs to cure PD. Current therapy provides only symptomatic treatment to the PD patients.
Due to the importance of RET signaling in the dopamine system as highlighted above, GFLs have
been tested both in preclinical and clinical settings. GFLs were found to promote the survival of
midbrain dopamine neurons both in vitro and in vivo [37,48,49]. Furthermore, GFLs provide both
neuroprotection and neurorestoration when studied in various toxin-based models of PD in rodents
and primates [48,50–57]. Based on the promising results in preclinical studies, clinical trials were
conducted with GDNF and NRTN. However, the outcomes of the clinical trials performed with GFLs
in PD patients are inconclusive. PhaseI/II clinical trials conducted using recombinant GDNF and
adeno-associated virus 2 encoded NRTN (AAv2-NRTN, CERE-120) indicated that both treatments
were well-tolerated. The improvement in motor performance of at least some patients was seen along
with an increase in [18F] DOPA uptake in the brain [58–60]. The last parameter indicates an increase in
function and likely the level of dopamine transporter, which suggests the restoration of dopamine
neuron terminals into putamen.
Despite promising preliminary data, in double-blinded placebo-controlled trials with both of these
GFLs, a statistically significant improvement in motor function of patients was not achieved. However,
an increase in [18F] DOPA uptake in the brains of PD patients was detected [61–64]. According to
the data from the double-blinded placebo-controlled study carried out with AAv2-NRTN, early-stage
PD patients benefited from the treatment more when compared to advanced-stage PD patients [65].
Moreover, post hoc analysis of recent clinical trials with GDNF revealed an improvement in motor
function in 43% of the patients treated with GDNF [63,64]. We have provided a detailed review of the
results of clinical trials conducted with GDNF and CERE-120 in our previous review [66].
While GFLs proteins had limited success in clinical trials in PD patients, targeting RET can
still be a valid approach for PD treatment. The poor tissue distribution of GFLs caused by their
binding to heparan sulfate proteoglycans might have resulted in partial coverage of the putamen in
PD patients, which was insufficient to observe statistically significant improvement in motor scores.
The main participants of clinical trials with GFLs were late-stage PD patients. As a result of ethical
reasons associated with the invasiveness of GFL delivery, it is very difficult to recruit early-stage
patients into these clinical trials. In the brains of these patients, most of the dopamine cell bodies and
fibers have already degenerated, and hence they are unlikely to benefit from GFL-based therapy [53].
The problems associated with GFLs delivery into the brains of PD patients can be solved by developing
small molecule RET agonists with better pharmacokinetics and pharmacodynamics properties crossing
the blood–brain barrier. This will allow including early-stage PD patients into clinical trials. Thus,
targeting RET in PD patients can be a disease-modifying strategy, but further research is needed to
reach this goal.
3.2. Retinitis Pigmentosa and Other Eye Diseases
RP is a rare genetic disorder with a prevalence of approximately 1:4000, which is caused by the
degeneration of photoreceptors in retina [67,68]. Degeneration starts from rods on the periphery, but at
the latter stage, cones in the macula and fovea are also affected. Symptoms include loss of night and
peripheral vision, which worsen with time, leading eventually to complete blindness. The death of
photoreceptors is accompanied by the accumulation of pigment on the periphery of retina seen during
ophthalmological examination [67,69]. The condition is incurable. Some reports suggest protective
effects of vitamin A and fish oils in RP patients, but the recent Cochrane systematic review concludes
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that the benefits of these treatments are uncertain [68]. The genetics of RP is diverse and complex;
mutations in more than 40 genes were found to be associated with the disease [70]. This complicates
the development of gene-therapy based approaches to treat RP.
In some animal models of RP, AAv-encoded GDNF slowed down the morphological and functional
deterioration of retina [71,72]; however, high levels of GDNF secretion accelerated the degeneration of
photoreceptors. Other authors failed to see protective effects of GDNF in animal models of RP [73,74],
while detecting an effect of RET activation by e.g., small molecular weight agonist [73]. A lack of
GDNF efficacy in RP can be related to the level of transgene expression [73] or poor diffusion of the
protein in the eye [74]. GDNF also exerted trophic effects toward axotomized retinal ganglion cells [75],
thus unraveling its potential usefulness for the treatment of glaucoma. These results establish RET as a
target for novel therapeutics in above-mentioned eye diseases.
GDNF-supportive effects toward photoreceptors are indirect and mediated by retinal glial cells
(Müller cells), which express both GFRα and RET [30,31]. Müller cells secrete various trophic factors
and are critical for the survival of retinal neurons in diabetes. Therefore, targeting GDNF receptor RET
with either protein, peptide, or small molecule ligand potentially can also slow down the progression
of diabetic retinopathy [76,77].
3.3. Hirschsprung Disease (HSCR)
HSCR is a rare disease (population incidence 1:5000 live births) caused by a disturbance in the
development of the enteric nervous system and characterized by the absence of enteric ganglion cells in
a part of the lower gastrointestinal tract that is variable in length [36,78]. The main treatment strategy
is surgical removal of the affected portion of intestine, but the motility problems remain, thus limiting
the long-term therapeutic efficacy of this approach.
Genetic factors play a major role in the pathogenesis of HSCR, with RET being the primary gene
associated with the disease. Mutations in RET were found in approximately 50% of patients with
familial HSCR and up to 20% of sporadic cases [78]. According to recent metaanalysis data, mutations
associated with HSCR can occur almost in any site of Ret, but they are most commonly found in exons
13 (11.32%), 15 (7.55%) (both coding RET kinase domain), and 10 (7.55%) (coding a part of cystein-rich
domain) [79,80]. These mutations are inactivating; they abrogate RET signaling, which leads to the
prevention of neural crest cell migration and distortions of the enteric nervous system. The earlier
in development mutation occurs and neural crest cell migration is blocked, the longer aganglionic
segment will be [80]. In animal models, the down-regulation of GFRα1 expression also resulted in
HSCR [81] and in biopsies of a subset of HSCR patientsa reduced level of GFRα1 protein was detected,
further supporting the role of the GFL/GFRα/RET axis in the development of this condition [82].
3.4. Neuropathic Pain
Neuropathic pain is defined by the International Association for the Study of Pain as a “pain that
arises as a direct consequence of a lesion or diseases affecting the somatosensory system” [83]. It affects
up to 10% of adults [84] and imposes significant economic burden on the society. According to Schaefer
et al., the estimated total annual costs of neuropathic pain were equal to 27,259 USD per patient [85].
Neuropathic pain can appear as a result of traumatic nerve lesion, disease e.g., diabetes, viral infection,
cancer or as a side effect or treatment with e.g., anticancer drugs or opioids [86,87], and it is more
common in women and the elderly [86]. Thus, due to an increase in the prevalence of underlying
conditions and aging population, the number of affected people is expected to grow in the future.
The treatment of neuropathic pain is a challenge for healthcare professionals. Available
drugs poorly manage the condition. Any given analgesic produces at least 50% pain in less than
30% of patients [88] and with any combination of existing drugs, adequate pain control can be
achieved in approximately half of patients. Tolerance and dependence are common side effects of
currently available analgesics. Neither of the drugs used nowadays to treat neuropathic pain is
considered disease-modifying.
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In neuropathic pain states, sensory neurons are damaged. RET and GFRα co-receptors are
expressed in a significant portion of healthy sensory neurons, and their expression is upregulated
after lesion in rodents [89]. Up to 80% of human sensory neurons express RET [90]. GFLs promote
the survival of sensory neurons and therefore have a disease-modifying potential in neuropathic
pain. However, their involvement in nociception is complex, and effects can depend on the dose,
administration schedule, administration site, condition of animals, and a disease model. In our recent
review, we described these issues in detail [66].
In several models of neuropathic pain, GDNF and ARTN were shown to provide analgesic effect
and restore lesioned sensory neurons [91–93], thus showing disease-modifying potential. However,
in inflammatory models, they seem to increase pain. In recent clinical trials, good tolerability and
the efficacy of ARTN in neuropathic pain patients was observed. However, the dose–response curve
was biphasic [94]. Importantly, ARTN provided pain relief in a population of patients resistant to the
therapy with at least two standard analgesics [94]. These patients are difficult to treat and truly in need
of novel drug classes.
Adverse events seen in clinical trials mainly included changes in temperature perception, headache,
pruritus, and rash, and they were mild or moderate in severity [95]. Since GFLs can signal also through
different receptors than RET, some effects of GFLs in the sensory system, e.g., cold-induced pain, can be
non-RET mediated [96,97].
A single cell transcriptome analysis of mouse sensory neurons revealed 11 subtypes of these cells.
RET was expressed in low-threshold mechanoreceptors responsible for pain elicited by mechanical
stimulation (which is often tested in preclinical models), neurons responsive for itchy feeling, and some
others [98]. Thus, pruritus reported in some patients treated with ARTN in clinical trials as an adverse
event is likely RET mediated.
It is clear that RET- and GFL- signaling plays an important role in pain and analgesia. However,
more data are needed to understand the exact action of each component of the GFL/GFR/RET axis
in these processes. The results of clinical trials are promising. Research focused on understanding
the molecular and cellular consequences of RET activation in the sensory system, as well as on
the evaluation of efficacy and safety of RET targeting molecules in preclinical and clinical settings,
is important for the development of novel disease-modifying treatments against neuropathic pain.
3.5. Role of RET in the Non-Homeostatic Regulation of Body Weight
Obesity and overweight are the conditions defined as excessive fat deposition that can result
in diabetes, cardiovascular diseases, osteoarthritis, and cancer. According to the World Health
Organization (WHO), in 2016, 1.9 billion people were overweight, and among them, 600 million people
were obese. Body weight and feeding behavior are regulated both by homeostatic and non-homeostatic
control mechanisms. Under homeostatic conditions, feeding behavior and energy metabolism are
controlled by hypothalamic neural circuits by integrating nutrient and hormonal signals from the
periphery [99]. However, during stress conditions, an organism uses an alternative program in order
to achieve metabolic changes [100]. Recently, GDNF receptor alpha-like (GFRAL), which is expressed
in the neurons of the area postrema and nucleus of the solitary tract, has been identified as the target
receptor for GDF15 that regulates food intake during stress conditions. GFRAL-GDF15 requires
RET as a signaling receptor through which it regulates body weight [23,24,26]. Intriguingly, RET is
expressed in the area postrema and nucleus of the solitary tract of rodents and human [101]. However,
RET phosphorylation and its downstream signaling events in GFRAL-positive neurons remain to
be elucidated.
3.6. Role of RET in Cancer
RET was discovered as a protooncogene, and its oncogenic potential has always been
acknowledged. A lot of research has been conducted on mutated constitutively active forms of
RET, which play a major role in thyroid cancer, pheochromocytoma, and parathyroid hyperplasia,
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as well as in the development of lung cancer in a subset of patients. In recent years, the reports
regarding the role of wild-type RET activated by its cognate ligands in the progression of tumors
originating from other tissues started to appear [102,103], but this field is much less studied, and final
conclusions are yet to be made.
Clinical features of RET-dependent cancers and extensive data on RET expression in different
tumor types are reviewed elsewhere [29,102–104]. In the present review, we focus rather on neglected
aspects of GFL/GFRα/RET signaling in the context of oncogenic transformation providing only a
minimal background on the above-mentioned issues. In particular, we discuss the differences between
the constitutive and ligand-induced activation of RET and possible involvement of GFL co-receptors in
tumor progression and invasion.
3.6.1. Oncogenic Potential of Constitutively Active Oncogenic Forms of RET
The ligand-independent activation of RET is caused by gain-of-function mutations manifesting
clinically as MEN2 or the formation of a fusion protein containing the intracellular kinase domain
of RET and N-terminal domain from another protein with the ability to dimerize, resulting in the
development of papillary thyroid carcinoma (PTC) [102,105]. RET bearing gain-of-function mutations
is constitutively active and continuously stimulates signaling cascades such as ERK and PI3K/Akt in
the cells promoting proliferation, survival, and metastasis [106]. In contrast to physiological conditions,
the activation mechanisms in the above-listed intracellular cascades in the presence of mutated RET are
not balanced by the negative regulation mechanisms, further contributing to the process of oncogenic
transformation of the cell [107].
MEN2 is diagnosed in 5–10% of thyroid cancer patients and includes three conditions: MEN2A
accounting for the vast majority of MEN2 cases, familial medullary thyroid carcinoma (FMTC)
occurring in 10–20% of MEN2 patients, and MEN2B identified in approximately 5% of MEN2 patients.
All MEN2 patients have medullary thyroid carcinoma, and approximately 50% of MEN2A and
MEN2B patients also develop pheochromocytoma. In addition, 20–30% of MEN2A patients also have
parathyroid disease. The MEN2B phenotype is the most aggressive, has early onset, and if untreated
by thyroidectomy, it leads to death in half of patients by the age of 25 years. Patients with MEN2B
mutation in RET (mainly Met918Thr) are recommended to undergo prophylactic thyroid surgery
during their first year of life, while for others, surgery is suggested within the first 5 years of life or even
later [104]. Mutations in RET are identified in approximately 50% of patients with sporadic medullary
thyroid carcinoma [25].
In patients with MEN2A, mutations occur in the extracellular domain of RET and lead to the
ligand-independent formation of a covalent dimer, whereas in patients with MEN2B, the mutations
typically occur in the RET kinase domain and are accompanied by an activation of monomeric form.
The most common mutation leading to MEN2A is C634X, and the most common mutation leading to
MEN2B is M918T [103]. In FMTC, mutations are found in both intracellular and extracellular domains
of RET [103,105].
PTC is the most common thyroid cancer. It is associated with RET rearrangements in 35% of
patients from North America, and in other populations, it can vary from 25 to 65% [103,108]. A higher
incidence of RET/PTC rearrangement is seen in children, and upon exposure to radioactive iodine
isotopes [109], for instance, RET/PTC rearrangements were identified in 51.3–77% of tumor specimens
collected from 5–18-year-old children exposed to radiation after Chernobyl reactor meltdown, while in
non-exposed children, their prevalence was below 40% [109].
RET kinase domain fusion with kinesin family member 5B was identified in about 1–2% of patients
with non-small-cell lung cancer (NSCLC), who were negative for mutations or rearrangements in
other common oncogenic drivers such as EGFR, HER, ERBB2, BRAF, KRAS, ALK, etc. [110–112].
In addition, in some patients with lung cancer M918T (MEN2B) RET mutation and fusion with other
proteins was identified [102,103]. Also approximately 3% of melanocytic neoplasms are positive for
RET fusion [113].
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RET/PTC isoform expression was detected in breast cancer tumors where it correlated with
estrogen receptor (EsR). In breast cancer cell lines, RET/PTC was expressed mostly in EsR-positive
cell lines. However, RET/PTC expression was not detected in most of the EsR-negative cell lines.
Estrogens were shown to transcriptionally upregulate RET/PTC expression [114].
It is important to note here that the signaling elicited by mutated RET is different in nature
compared to the signaling produced by RET ligands such as GFLs. Mutated isoforms of RET
are constitutively active for a long period of time. The signaling elicited by GFLs is pulsatile and
self-limiting via degradation of the ligand and receptor by proteases, activation of silencing mechanisms,
e.g., triggering the activation of phosphatases dephosphorylating RET [115] and negative feedback
loops in intracellular signaling cascades [116–118]. The combination of these events leads to rapid
quenching of the signal elicited by GFL. Interestingly, in the presence of the constitutively active forms
of RET, the mechanisms of its negative regulation are also activated [115]. However, in this case,
the persistent presence of receptor stimulation leads to oscillatory patterns of intracellular signaling
(e.g., ERK signaling cascade) activation (Sidorova et al., unpublished observation), which is also
predicted to occur in the presence of natural ligand. Nevertheless, in the presence of natural ligands,
these oscillations are difficult to detect experimentally due to their small amplitude, short duration,
and rapid changes [115]. Importantly, a constitutively active RET signals not only on the cell surface
but also in ER during the process of protein maturation. RET MEN forms are already active in ER and
signal on their way to the cell surface. RET/PTC variants signal in various cellular compartments [105].
Wild-type RET signaling occurs in lipid rafts where it is recruited by GFRα co-receptors. Transition
to rafts is necessary for the efficient activation of intracellular signaling pathways and subsequent
events on the cell and tissue level, e.g., cell survival, organ formation [28,119]. Mutated RET variants
can also trigger intracellular cascades being outside lipid rafts, since they signals in the absence of
co-receptor and the process of their recruitment to raft is GFRα -dependent; therefore, the pattern of
activated secondary messengers can be different for wild-type and mutated RET. Despite mechanistic
spatio-temporal differences in signaling, ligand-activated RET is considered to be able to contribute to
the invasion of tumor cells and the progression of oncogenesis, as described in the next chapter.
3.6.2. Oncogenic Potential of Wild-Type RET
Extensive in vitro data unequivocally demonstrate that in breast cancer cell lines, GDNF promotes
cell migration and survival in an RET-dependent manner, rendering cells insensitive to anticancer
drugs targeting EsR or aromatase. Similarly, the proliferation and survival of pancreatic and prostate
cancer cell lines that often express GFRα1 and RET can be promoted by GDNF [120–123].
The pharmacological inhibition of RET with panspecific kinase inhibitors restores the sensitivity
of breast cancer cell lines to tamoxifen, fulvestrant, and letrozole [124–126]. In animal models,
additive effects of treatment with a combination of anti-EsR agent and RET inhibitor on tumor size
were not detected, although the metastatic index in lungs was lower in the case of dual inhibition of
RET with panspecific kinase inhibitors and EsR with tamoxifen [126]. There is also a link between
inflammation, which often accompanies oncogenesis, and RET expression. The effects of inflammatory
cytokine interleukin 6 (IL-6) on the migration of breast cancer cell lines were abolished in the presence
of kinase inhibitors, although this interleukin does not activate RET directly [126]. At least in breast
cancer cells, inflammatory mediators may upregulate GDNF expression, thus indirectly triggering
RET signaling [125]. However, specific RET inhibitors are not available, and existing molecules target
broad spectrum of various kinases, although with different affinity. IL-6 signals via glycoprotein 130,
which activates multiple intracellular signaling cascades that are heavily dependent on the processes of
protein phosphorylation [127]. Therefore, the treatment of the cells with a kinase inhibitor can abolish
IL-6 signaling independently of RET as well.
Analysis of clinical samples collected from patients with breast tumors also demonstrates the
overexpression of RET in a significant portion of these specimens. However, there is a discrepancy
in the percentage of the breast tumors overexpressing RET between the data collected using
Int. J. Mol. Sci. 2020, 21, 7108 11 of 21
immunohistochemical and mRNA-level assessment methods. Gatteli et al. reported the presence of
RET protein overexpression in 74% of breast tumors and found a positive correlation between the level
of RET protein and metastasis-free and overall survival. At the same time, an elevated mRNA level
of RET was detected only in 30–40% of breast cancer biopsies, and this parameter did not correlate
with lymph nodes metastasis or lymphovascular invasion [4,128]. On the contrary, elevated levels of
GFRα1 mRNA were detected in almost 60% of patients’ samples, and they correlated with the invasion
and metastasis of breast cancer cells. Only 18.1% of tumors were double positive for RET/GFRα1
based on mRNA analysis data [4]. However, RET can also transmit a signal from GDNF in a complex
with soluble GFRα1 [9] produced by e.g., neuronal cells. The percentage of GFRα1-negative RET
positive breast tumors in the study by Essiger et al. was 0.9%; thus, the other three GFR co-receptors
are unlikely to have a major contribution in GFL-mediated effects in breast cancer [4].
While the discrepancy between immunohistochemistry and mRNA level data can be explained
by the difference in the patient populations and the data analysis setup, it is also possible that technical
artifacts related to the unspecific binding of RET antibodies to breast biopsies led to the overestimation
of GDNF/GFRα1/RET role in the breast cancer. Many antibodies against GDNF, GFRα1, and RET are
not specific and produce staining also in tissue sections from knockout animals [129]. The specific
antibodies to RET have only been characterized in rodents a few years ago [113]. Therefore, it is
important to support immunohistochemical findings with the data on the transcription of these genes.
The overexpression of RET was also detected by immunohistochemical methods in 40–65% of
samples from pancreatic tumors and 20–75% of samples from prostate cancer as well as in samples
from other cancers (reviewed in detail by Mullican, 2019 [24]), and it is generally correlated with
worse prognosis and more advanced tumor stages [102,121,122]. There are also immunohistochemical
data showing the overexpression of GFRα1 and co-expression of GFRα1 and RET in these specimens,
at least in some cases. However, similar to breast cancer data, no significant correlation between
the expression of other GFL co-receptors and prognosis for pancreatic cancer patients was identified.
Taking into account the data for breast cancer samples described above, it is obvious that a more
detailed characterization of biopsies from patients with pancreatic, prostate, and other cancers for
the expression of components of GFL signaling complex using more reliable methods of mRNA level
analysis can actually change the overall impression regarding the role of RET in these malignancies.
RET differs from other receptor tyrosine kinases in regard to kinase domain activation by
phosphorylation. RET has intrinsic catalytic activity, and its enzymatic activity is only slightly
increased upon the phosphorylation of tyrosine residues, at least in in vitro settings [5]. This can
imply the presence of inhibitory mechanisms in the cells limiting the intrinsic activity of RET. These
mechanisms can be overloaded in the case of RET overexpression, and RET can become activated in
the absence of ligand.
Evidence collected in cell cultures showing the effects of pharmacological RET inhibition on
survival and proliferation should be interpreted with caution. Specific or even highly selective RET
inhibitors are yet to be developed. Compounds used in such research target multiple intracellular
kinases. Considering the central role of phosphorylation processes for cell functioning and division,
it is not surprising that in the presence of panspecific kinase inhibitors, the survival of cancer cells is
diminished. With this, we would like to stress that we by no means try to belittle the relevance of these
kinase inhibitors in cancer therapy. However, the data produced with these inhibitors in cancer cell
lines shed little light on the role of RET in oncogenesis.
It is important to remember that GDNF in complex with GFRα1 can also signal RET independently
via neural cell adhesion molecule (NCAM) and GFRα1 independently through syndecan-3 [130,131].
Generally, GFRα1 is expressed in the organism more widely than RET. Since, based on an analysis
of mRNA levels, the overexpression of GFRα1, but not RET, in the breast cancer has been shown to
be associated with cancer metastasis and invasion [4], it is possible that RET-independent, GDNF,
and GFRα1-dependent events play a significant role in the tumor malignization process. Further studies
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are needed to clarify the role of each component in the GDNF/GFRα1/RET pathway in regard to its
oncogenic potential.
Recent evidence obtained in mice overexpressing GDNF in moderate levels (by 2 fold compared
to wild-type littermates) revealed no enhancement of tumor formation during their life span [132].
In addition, infusions of GDNF protein or the overexpression of NRTN from viral vectors in the brain
of PD patients as well as systemic injections of ARTN to neuropathic pain patients did not seem
to be associated with oncogenesis [98]. Thus, the ligand-induced pulsatile activation of wild type
non-overexpressed RET by natural or artificial ligands may not be related with tumor formation or
progress and thus can be safe for patients.
4. Targeting RET with Small Molecule for the Treatment of Diseases
RET plays an important role in the maintenance and survival of both dopamine and sensory
neurons, as well as retinal cells. In addition, activating RET in the brainstem region can be a therapeutic
strategy for the treatment of obesity. GFLs are considered as potential therapeutics agents for the
treatment of various diseases. However, they are not drug-like molecules. GFLs do not cross the
blood–brain barrier (BBB); therefore, they have to be delivered via complicated brain surgery in
PD. GFLs have higher affinity to the extracellular matrix and proteoglycans, which results in poor
distribution in the tissues. In addition, production, stability and long-term storage are the other
challenges of protein drugs. Protein drugs can very easily be susceptible to both physical and chemical
damages, often making them biologically inactive. Further, recombinant protein drugs have a shorter
half life, making them unsuitable for therapy [133].
GFLs often have more than one target receptor. For example, GDNF functions via heparan sulfate
proteoglycan syndecan-3 [134], NCAM [91–93], and RET receptor. This might result in undesirable
effects of GFLs. Therefore, developing small molecules targeting RET selectively would solve the
drawbacks associated with GFLs as drugs. Small molecules can cross BBB and may have better tissue
distribution then GFLs. In addition, small molecules can be given orally or through injection, by which
complicated surgery needed for their delivery to the brain can be avoided.
We have screened and developed the first and second generation of three structurally
unrelated RET agonists (BT, HUS, and Q compounds) and tested them both in in vitro and in vivo
assays [3,44,45,74,135,136]. Compounds from the BT scaffold were tested in animal models of PD
and neuropathic pain. BT13 was shown to support the survival of naive cultured dopamine neurons,
protect cultured dopamine neurons from toxin-induced cell death, and promote neurite outgrowth
from cultured sensory neurons [3]. BT13 was also able to alleviate motor deficits in the 6-OHDA
model of PD as well as attenuate neuropathy-induced pain-like behavior in the rat neuropathic
pain model [135]. The second generation BT compounds, BT44, alleviated pain in surgery-based
and diabetes-induced models of NP [136]. The second and the third group of RET agonists (Q and
HUS compounds), which have better pharmacokinetic and pharmacodynamics properties than BT
compounds, support the survival of photoreceptor neurons in ex vivo animal model of RP and activate
prosurvival intracellular signaling in retina in vivo [3,74]. However, Q and HUS compounds have not
been tested in other disease models such as PD, neuropathic pain, and the animal model of obesity.
Further development of these compounds can eventually result in the generation of disease-modifying
drugs against neurodegeneration and obesity.
The potential mechanism of action on the molecular level was studied for BT compounds using
molecular dynamic simulation and docking methods. The combination of in silico and in vitro data
indicates that these small molecules most likely bind to RET on RET/GFRα interaction interface,
thus mimicking a complex of GFL-GFRα [137]. This possibly results in a change in RET conformation
and increase in RET kinase activity, resulting in RET phosphorylation and the subsequent activation
of intracellular cascades. However, further studies are needed to understand if other agonists target
the same binding site and to identify molecular changes occurring in the RET molecules after the
stimulation with small molecular weight agonist.
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Due to the well-established role of RET in various types of cancers, its antagonists are important
for antitumor therapy. The development of specific RET inhibitors is rather challenging, since the RET
kinase domain is similar to that of other RTKs. However, a number of small molecular weight kinase
inhibitors approved for anti-cancer therapy also act as RET antagonists. These molecules also target
other RTKs, among those vascular endothelial growth factor receptors. Although this feature makes it
difficult to dissect the effect of only RET inhibition in cancer treatment, it can be very useful from the
therapeutic point of view, because such compounds can also reduce tumor vascularization. In addition,
the process of tumor evolution may lead to the development of resistance to the compounds specifically
targeting a single RTK. Thus, the identification of specific RET antagonists is an interesting scientific
task, and it is important to understand the role and mechanism of RET involvement in carcinogenesis,
but therapeutically, such inhibitors may be less attractive. Therefore, current efforts in this field are
mainly focused on the development of polyspecific kinase inhibitors with acceptable safety profiles.
A detailed review describing the effects, targets, and specificity of individual kinase inhibitors with a
focus on RET was recently published by Falco and co-authors [79,138].
The limitation of the present review is in it’s scope. Here, we mostly focused on various
conditions where both RET and GFLs are extensively studied, and the clinical potential of RET
modulation is well-established. Therefore, this review is limited to the potential role of RET in some
neurodegenerative diseases, cancer, and obesity. However, RET is expressed in several various tissues
and also in different neuronal populations such as dopamine neurons, motor neurons, sympathetic
neurons, and parasympathetic neurons [31–33,139]. RET also regulates development of the kidney [39],
but importance of RET in kidney diseases has not been reported yet. Further, RET-dependent signaling
may play a role in other diseases and conditions e.g., amyotrophic lateral sclerosis (ALS) [140] and
addiction [141]. In some tissues e.g., the hippocampus, the expression of RET is negligible in normal
conditions but can be upregulated upon lesion [142]. RET can be also differently expressed in tissues
of experimental animals and humans. Therefore, the modulators of RET signaling can on one hand
be evaluated for efficacy in a number of different conditions, but on the other hand, the developed
agonists may produce some target-related adverse effects. Therefore, further studies are needed to
evaluate the role of each component of GDNF/GFRα/RET in health and disease states and develop
efficient therapeutics targeting these proteins.
5. Conclusions and Perspectives
Due to the importance of RET-dependent signaling for neuronal survival and appetite control,
targeting this pathway with agonists may result in the development of novel disease-modifying
treatments against neurodegenerative disorders, chronic pain, and obesity, all of which represent major
challenges for healthcare in the modern world. Attempts to use natural ligands of RET, which are GFL
proteins for this purpose, achieved so far rather limited success because of their poor pharmacological
characteristics. Obvious alternatives to GFLs for clinical use are small molecular weight agonists
of RET, GFRα, or GFRα/RET as well as GFL-derived peptides, a few of which have recently been
discovered. However, the development of these compounds has been hindered by concerns regarding
the oncogenic potential of RET activation. Based on the data presented in the current review, it is
clear that understanding the role of wild-type RET in oncogenesis requires further studies. Available
data suggest that GFRα rather than RET may be involved in the malignization process, while the
short-term pulsatile moderate activation of wild-type non-overexpressed RET by natural or artificial
ligands can be safe for patients. Therefore, RET agonists targeting RET described in the review can
represent an important step forward in the development of novel treatments for neurodegeneration,
pain, and obesity.
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AAv Adeno-associated virus
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BBB Blood–brain barrier
CERE-120 Adeno-associated virus-encoded neurturin
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GDF15 Growth differentiation factor-15
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